唑来膦酸治疗骨质疏松不良反应影响因素及防治的研究进展

Research progress on influencing factors and prevention of adverse reactions of Zoledronic Acid in the treatment of osteoporosis

骨质疏松症是目前全球性健康问题之一,严重影响患者身体健康和生活质量。双膦酸盐是目前国际推荐治疗骨质疏松症的一线药物,而唑来膦酸作为第三代双膦酸盐药物的代表,具有强效抗骨吸收的疗效,能有效缓解骨质疏松症状,临床应用广泛。但随着研究的深入,越来越多医务工作者在报道中指出运用唑来膦酸时存在多种不良反应,临床中发现急性期反应、颌骨坏死、眼球并发症、肾损伤、低钙血症等不良反应发生率较高或症状较重。本文就唑来膦酸治疗骨质疏松症的作用机制、不良反应、影响因素与防治的研究进展进行综述,以期为临床运用唑来膦酸提供参考。

Osteoporosis is one of the global health problems,which seriously affects the health and quality of life of patients.Bisphosphonates are currently the first-line drugs recommended by the international community for the treatment of osteoporosis.As the third-generation bisphosphonates,Zoledronic Acid is widely used in clinical practice because of its strong anti-bone resorption effect and effective relief of osteoporosis symptoms.However,with the deepening of research,more and more medical workers have pointed out in their reports that there are many kinds of adverse reactions when using Zoledronic Acid,and the incidence of acute phase reaction,osteonecrosis of the jaw,ocular complications,kidney injury,hypocalcemia and other adverse reactions is higher or the symptoms are more serious in clinical practice.In this paper,the mechanism,adverse reactions and their influencing factors,prevention and control of adverse reactions of Zoledronic Acid in the treatment of osteoporosis are reviewed to provide a reference for clinical use of Zoledronic Acid.